# Biofrontera Inc.

Type: Company (BFRI)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/biofrontera-inc
Canonical HTML page: https://getbiobrief.com/entity/biofrontera-inc

## Recent coverage (2 stories)

### Biofrontera and DarioHealth Signal Commercial Pivot in Q4 2025 Results
2026-03-19 17:04:35 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biofrontera and DarioHealth reported Q4 2025 results that underscore a strategic shift toward high-margin clinical and enterprise markets. Both companies are prioritizing a path to profitability through disciplined cost management and the expansion of recurring revenue streams in dermatology and digital chronic care.
Full story: https://getbiobrief.com/story/biofrontera-dariohealth-q4-2025-earnings-analysis

### Biofrontera Inc. Reports Record 2025 Revenue Driven by PDT Market Expansion
2026-03-19 14:57:33 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biofrontera Inc. (BFRI) has achieved record financial results for the fourth quarter and full year 2025, signaling a significant shift in the dermatology market toward photodynamic therapy. The company's performance reflects robust adoption of its flagship product, Ameluz, and its proprietary RhodoLED lamp technology in the United States.
Full story: https://getbiobrief.com/story/biofrontera-record-2025-financial-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.